BMY recently won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults. The drug was approved under the brand name ...

Bristol Myers Squibb BMY announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency for two of its drugs. The ...

“KarXT is the first new class of treatment for ... as compared to current antipsychotic medicines, which mostly target dopamine or serotonin receptors. Zai Lab has an exclusive license from ...

“KarXT is the first new class of treatment for ... as compared to current antipsychotic medicines, which mostly target dopamine or serotonin receptors. Schizophrenia is a persistent and often ...

GlobalData has predicted that – if approved – KarXT will achieve sales of $1.1 billion by 2031 thanks to its safety profile and ability to broadly target symptoms of schizophrenia, i.e. both ...

The US regulator has cleared the combination of muscarinic M1 and M4 agonist xanomeline tartrate and muscarinic antagonist trospium chloride – formerly known as KarXT – under the Cobenfy brand ...